DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Home › DRG Perspectives › Will Bioresorbable Vascular Stents...

Will Bioresorbable Vascular Stents Overtake Drug-Eluting Stents As The Gold Standard In CAD Treatment?

Publish date: 12 Jul, 2017

By Benjamin Li, Valentina Lim, and Durugshan Wijayakumar

Thank you for your interest in Will Bioresorbable Vascular Stents Overtake Drug-Eluting Stents As The Gold Standard In CAD Treatment? Please fill out the form below to access your whitepaper.

Biotech set for good start to 2021

View Now

Find a Report
Linkedin
Twitter
Contact Us

Will Bioresorbable Vascular Stents Overtake Drug-Eluting Stents As The Gold Standard In CAD Treatment?

Biotech set for good start to 2021

Company

Resources

Support

Social